logo-loader
RNS
4basebio PLC

Notice of Investor Presentation via Investor Meet Company

9 November 2026

 

4basebio PLC

("4basebio" or the "Company")

Notice of Investor Presentation via Investor Meet Company

CAMBRIDGE, UK - 9 November 2026 - 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces that Dr. Amy Walker, Chief Executive Officer and Richard Bungay, Chief Financial Officer, will provide a live investor presentation on the Investor Meet Company platform on 12 November 2026 at 17:00 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted before the event through the Investor Meet Company dashboard up until 11 November 2026, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to the Investor Meet Company platform for free and follow 4basebio PLC via:

https://www.investormeetcompany.com/4basebio-plc/register-investor

Investors who already follow 4basebio PLC on the Investor Meet Company platform will automatically be invited.

 

Contact Details

4basebio PLC

+44 (0)12 2396 7943

Dr. Amy Walker - Chief Executive Officer

Cairn Financial Advisers LLP (Nominated Adviser)

T: +44 (0)20 7213 0880

Jo Turner, Sandy Jamieson, Ed Downes

RBC Capital Markets (Joint Corporate Broker)

T: +44 (0)20 7653 4000

Kathryn Deegan - ECM

Max Avison - ECM Syndicate

Sandrine Cailleteau - Healthcare Advisory

Cavendish Capital Markets Limited (Joint Corporate Broker)

T: +44 (0)20 7220 0500

Geoff Nash, Andrea Callaghan - Corporate Finance

Nigel Birks - Healthcare Specialist Sales

ICR Healthcare (Media and Investor Relations)

T: +44 (0)20 3707 5700

Jessica Hodgson, Ashley Tapp, Philip Marriage

 

 About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality. 

For more information, visit 4basebio.com.

 Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

 

 




NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Holding(s) in Company

2 days, 2 hours ago

Holding(s) in Company

5 days, 23 hours ago

Holding(s) in Company

6 days, 23 hours ago

Holding(s) in Company

6 days, 23 hours ago

Holding(s) in Company

6 days, 23 hours ago

Result of General Meeting

1 week, 6 days ago

Result of Retail Offer

4 weeks, 1 day ago

6 min read